Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Open accessThe DOI matches its Crossref record; 191 of the 191 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis-driven by an imbalance of pro- and antiangiogenic signaling-is a hallmark of many diseases, both malignant and benign. Unlike in the healthy adult in which angiogenesis is tightly regulated, such diseases are characterized by uncontrolled new vessel formation, resulting in a microvascular network characterized by vessel immaturity, with profound structural and functional abnormalities. The consequence of these abnormalities is further modification of the microenvironment, often serving to fuel disease progression and attenuate response to conventional therapies. In this article, we present the "vascular normalization" hypothesis, which states that antiangiogenic therapy, by restoring the balance between pro- and antiangiogenic signaling, can induce a more structurally and functionally normal vasculature in a variety of diseases. We present the preclinical and clinical evidence supporting this concept and discuss how it has contributed to successful treatment of both solid tumors and several benign conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Antiangiogenic agents are thought to normalize tumor vasculature to allow for better delivery of chemotherapy.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 2×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundRanibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundTumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundCancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 2×
“The discovery of vascular endothelial growth factor (VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folk…”
BackgroundIntegrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 4×
“…(VEGF) as the principal driver of tumor angiogenesis (Senger et al. 1983; Leung et al. 1989) rapidly prompted the development of antiangiogenic drugs to treat cancer, designed to inhibit VEGF’s activity and hence promote vascular regression and tumor starvation (Folkman 1971; Kim et al. 1993).”
BackgroundInfluentialPaclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847 · cited 1×
“The angiopoietin-Tie2 pathway is perhaps the second most important EC-specific pathway regulating both healthy and tumor-associated angiogenesis (Suri et al. 1996; Huang et al. 2010).”
BackgroundMolecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438 · cited 1×
“At the cellular level, proangiogenic factors induce weakening of VE-Cadherin-mediated endothelial cell (EC) junctions and EC migration, altering vessel wall architecture (Hobbs et al. 1998; Hashizume et al. 2000).”
BackgroundSelf-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339 · cited 2×
“(Ebos et al. 2009; Paez-Ribes et al. 2009).”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“In turn, this normalized vessel phenotype dramatically alters the retinal microenvironment and has led to impressive clinical results (Gragoudas et al. 2004; Rosenfeld et al. 2006; Ferrara 2010), including improved visual acuity lasting for up to 24 mo after commencement of therapy.”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · cited 1×
“Unfortunately, results using such agents in clinical trials have been disappointing, with antiangiogenic monotherapy generally failing to invoke significant response rates or prolongations of survival in solid tumor patients (Jain et al. 2006; Giantonio et al. 2007).”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 6×
“2) (Willett et al. 2004, 2005, 2009).”
BackgroundMethodInfluentialSelf-citationBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769 · cited 11×
“Because serial tissue biopsies cannot be obtained from recurrent GBM patients, advanced “vascular” MRI was used to assess changes in vessel structure and function.”
BackgroundInfluentialSelf-citationBrowder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,720
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709 · cited 2×
“(Ebos et al. 2009; Paez-Ribes et al. 2009).”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689 · cited 1×
“At the cellular level, proangiogenic factors induce weakening of VE-Cadherin-mediated endothelial cell (EC) junctions and EC migration, altering vessel wall architecture (Hobbs et al. 1998; Hashizume et al. 2000).”
BackgroundSelf-citationCarmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., De Mol, M., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,672 · cited 2×
“…tissues, but is found abundantly in various tumors (Fischer et al. 2007), and plays an important role in tumors through stimulation of EC growth, mobilization of bone marrow cells, and recruitment of macrophages (Carmeliet et al. 2001) through its binding to VEGFR1 and its coreceptors NRP1 and 2.”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 1×
“More recently, similar abnormalities in vessel structure and function have been reported in a number of nonmalignant diseases (Carmeliet and Jain 2011; Goel et al. 2011).”
BackgroundSelf-citationReck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,505 · cited 1×
“Intriguingly, however, the addition of anti-VEGF therapy to systemic chemotherapy has often proven to be an effective strategy, with patient outcomes superior to chemotherapy alone (Hurwitz et al. 2004; Sandler et al. 2006; Miller et al. 2007; Saltz et al. 2008; Reck et al. 2009).”
BackgroundIntraplaque Hemorrhage and Progression of Coronary Atheroma
Kolodgie, F. D., Gold, H. K., Burke, A. P., Fowler, D. R., Kruth, H. S., Weber, D. K., Farb, A., Guerrero, L. J., Hayase, M., Kutys, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035655 · Cited by 1,486 · cited 2×
“atherosclerotic plaque development is a young and relatively unexplored area, evidence does suggest that new vessel formation in the coronary plaque vasa vasorum is an important contributor to disease progression and plaque complications (Jeziorska and Woolley 1999; Kolodgie et al. 2003; Virmani et al. 2005; Jain et a…”
BackgroundControl of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
Augustin, H. G., Young Koh, G., Thurston, G., & Alitalo, K. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2639 · Cited by 1,465 · cited 2×
“…Ang-1 is generally considered a Tie-2 agonist which promotes vessel maturity and stability and reduces leakiness (Thurston et al. 1999, 2000; Augustin et al. 2009) and Ang-2 serves as a competitive 8 Cite this article as Cold Spring Harb Perspect Med 2012;2:a006486 w w w .p er sp ec ti ve…”
BackgroundThe anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359 · cited 1×
“…are complex and context-dependent, Ang-1 is generally considered a Tie-2 agonist which promotes vessel maturity and stability and reduces leakiness (Thurston et al. 1999, 2000; Augustin et al. 2009) and Ang-2 serves as a competitive 8 Cite this article as Cold Spring Harb Perspect Med…”
BackgroundVirmani, R., Kolodgie, F. D., Burke, A. P., Finn, A. V., Gold, H. K., Tulenko, T. N., Wrenn, S. P., & Narula, J. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178991.71605.18 · Cited by 1,331 · cited 2×
“atherosclerotic plaque development is a young and relatively unexplored area, evidence does suggest that new vessel formation in the coronary plaque vasa vasorum is an important contributor to disease progression and plaque complications (Jeziorska and Woolley 1999; Kolodgie et al. 2003; Virmani et al. 2005; Jain et a…”
BackgroundDefinition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321 · cited 2×
“These include the EC-specific integrins (Friedlander et al. 1995; Kurozumi et al. 2007; Skuli et al. 2009; Desgrosellier and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et…”
BackgroundAngiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297 · cited 1×
“…are complex and context-dependent, Ang-1 is generally considered a Tie-2 agonist which promotes vessel maturity and stability and reduces leakiness (Thurston et al. 1999, 2000; Augustin et al. 2009) and Ang-2 serves as a competitive 8 Cite this article as Cold Spring Harb Perspect Med…”
BackgroundBenjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241 · cited 1×
“…edema, reduced patient need for corticosteroids (Batchelor et al. 2007, 2010) High grade glioma (n ¼ 5) Bevacizumab Vascular arcades and glomeruloid vessels Fischer et al. 2008 Prostate carcinoma (n ¼ 10) Androgen ablation Pruning of immature vessels, PVC coverage Benjamin et al. 1999”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 25×
“…“normalization window”—a time period beginning with the appearance of a normalized vascular phenotype (typically within 1–2 days of starting treatment), and ending when features of normalization are lost (Tong et al. 2004; Winkler et al. 2004; Jain 2005b; Batchelor et al. 2007; Kamoun et al. 2009).”
BackgroundInfluentialSelf-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · cited 10×
“…“normalization window”—a time period beginning with the appearance of a normalized vascular phenotype (typically within 1–2 days of starting treatment), and ending when features of normalization are lost (Tong et al. 2004; Winkler et al. 2004; Jain 2005b; Batchelor et al. 2007; Kamoun et al. 2009).”
BackgroundInfluentialSelf-citationLessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · cited 1×
“Unfortunately, results using such agents in clinical trials have been disappointing, with antiangiogenic monotherapy generally failing to invoke significant response rates or prolongations of survival in solid tumor patients (Jain et al. 2006; Giantonio et al. 2007).”
BackgroundSelf-citationAbnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 983 · cited 1×
“Similarly, the perivascular cells (PVCs, comprised of pericytes and vascular smooth muscle cells [VSMCs]) are often only loosely attached to ECs and are reduced in number (Morikawa et al. 2002; Abramsson et al. 2003; Jain 2003; Inai et al. 2004; Tong et al. 2004).”
BackgroundSelf-citationGorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 4×
“This leakiness, together with a relative absence of functional intratumoral lymphatic vessels (Padera et al. 2004; Hagendoorn et al. 2006), leads to a marked increase in the tumor interstitial fluid pressure (IFP) to a level that equilibrates with intravascular pressure, which results in reduced…”
BackgroundInfluentialSelf-citationMazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812 · cited 10×
“…seen in mice with an EC-specific single allele deletion of PHD2, suggesting that hypoxia (and hence PHD2 inhibition) drives ECs toward a normalized phenotype (as opposed to the effects of hypoxia on tumor cells which promotes VEGF expression and an abnormal vessel phenotype) (Mazzone et al. 2009).”
BackgroundInfluentialAnti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels
Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., De Mol, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 779 · cited 6×
“Pharmacological PlGF blockade has yielded conflicting results, with some reports demonstrating a profound effect on tumor growth accompanied by angiogenesis inhibition, vessel maturation, resolution of hypoxia, and improved efficacy of chemotherapy (Fischer et al. 2007; Van de Veire et al. 2010), and others demonstrat…”
BackgroundResultInfluentialInai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
(1990) · PubMed · Cited by 757
Self-citationTargeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752 · cited 1×
“Unlike physiological angiogenesis, blood vessel development in solid tumors is not tightly controlled, but rather occurs relentlessly (Dvorak 1986; Chung et al. 2010; Carmeliet and Jain 2011).”
BackgroundLee, C. G., Heijn, M., di Tomaso, E., Griffon, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., et al. (2000) · PubMed · Cited by 733
Self-citationYuan, F., Chen, Y., Dellian, M., Safabakhsh, N., Ferrara, N., & Jain, R. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14765 · Cited by 719 · cited 4×
“This has generally been accompanied by an increase in vascular maturity (the proportion of PVC-covered vessels), such that the treated vasculature resembles that of normal tissue more closely (Yuan et al. 1996; Inai et al. 2004; Tong et al. 2004; Dickson et al. 2007b).”
BackgroundInfluentialSelf-citationRolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 5×
“The histidine-rich glycoprotein (HRG), through its down-regulation of PlGF, may mediate this process, inducing vessel normalization and also modifications in tumor-associated macrophages from a protumor (M2) to antitumor (M1) phenotype (Huang et al. 2011; Rolny et al. 2011).”
BackgroundInfluentialMoulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688 · cited 1×
“For example, the angiogenesis inhibitors endostatin and TNP-470 have been shown to not only reduce new vessel formation within plaques, but also slow plaque growth (Moulton et al. 1999).”
BackgroundShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677 · cited 2×
“…al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and Gallo 2009; J Liu, S Liao, B Diop-Frimpong, et al., unpubl. data. hHuang et al. 2002; Li et al. 2006; Manning et al. 2007; Hamzah et al. 2008; Shrimali et al. 2010.”
BackgroundMazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639 · cited 1×
“Ang-2 inhibition operates not only through preventing Ang-2/Tie-2 interaction on ECs, but might also interfere with the proangiogenic activities of Tie-2 expressing monocytes (TEMs) (Coffelt et al. 2010; Mazzieri et al. 2011).”
BackgroundA role for VEGF as a negative regulator of pericyte function and vessel maturation
Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., Scheppke, L., Stockmann, C., Johnson, R. S., Angle, N., et al. (2008) · Nature · doi:10.1038/nature07424 · Cited by 629 · cited 4×
“When VEGF2/2 tumors are grown in wild-type animals, tumor vessels show improved PVC coverage (Greenberg et al. 2008).”
BackgroundInfluentialHerceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623 · cited 7×
“Investigators have reported various aspects of normalization in response to inhibition of several oncogenes including HER-2 (Izumi et al. 2002), the PI3K-AKT-mTOR axis (Pore et al.”
BackgroundInfluentialSelf-citationWhy are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611 · cited 2×
“…abundance of VEGF and other proangiogenic factors drives 2 Cite this article as Cold Spring Harb Perspect Med 2012;2:a006486 w w w .p er sp ec ti ve si n m ed ic in e. o rg continual angiogenesis and the production of an abnormal blood vessel network (Jain 2005a; Nagy et al. 2009).”
BackgroundVEGF as a Therapeutic Target in Cancer
Ferrara, N. (2005) · Oncology · doi:10.1159/000088479 · Cited by 578 · cited 2×
“Molecular stimuli within solid tumors (hypoxia, acidosis, oncogenic signaling, growth factors, sex hormones, and cytokines) all induce the formation of new vessels (Vogelstein and Kinzler 2004; Ferrara 2005; Carmeliet and Jain 2011).”
BackgroundBiomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572 · cited 1×
“Finally, biomarkers for vascular normalization are sorely needed to use this concept optimally in the clinical setting (Jain et al. 2009).”
BackgroundSelf-citationVascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564 · cited 7×
“…al. 2010. eSalnikov et al. 2005; Bhattacharya et al. 2008; Qayum et al. 2009. fBenjamin et al. 1999; Dickson et al. 2007a,c; Greenberg et al. 2008; Hamzah et al. 2008; Kashiwagi et al. 2008; Stockmann et al. 2008; di Tomaso et al. 2009; Maione et al. 2009; Mazzone et al. 2009; Nasarre et al.…”
BackgroundInfluentialAbramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18549 · Cited by 562 · cited 1×
“Similarly, the perivascular cells (PVCs, comprised of pericytes and vascular smooth muscle cells [VSMCs]) are often only loosely attached to ECs and are reduced in number (Morikawa et al. 2002; Abramsson et al. 2003; Jain 2003; Inai et al. 2004; Tong et al. 2004).”
BackgroundDelivery of Novel Therapeutic Agents in Tumors: Physiological Barriers and Strategies
Jain, R. K. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.570 · Cited by 557
Self-citationHearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., Halpin, C., Padera, T. P., Tyrrell, A., Sorensen, A. G., Jain, R. K., & di Tomaso, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902579 · Cited by 532 · cited 3×
“These features have been emphasized through the results of a clinical trial in NF2 patients (Plotkin et al. 2009).”
BackgroundSelf-citationBatchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520 · cited 9×
“Because serial tissue biopsies cannot be obtained from recurrent GBM patients, advanced “vascular” MRI was used to assess changes in vessel structure and function.”
BackgroundInfluentialSelf-citationWillett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508 · cited 2×
“Rectal carcinoma (n ¼ 32) Bevacizumab Vessel density, PVC coverage Tumor blood flow, IFP, improved delivery of FDG per vessel Tumors became pale (Willett et al. 2004, 2009) Glioblastoma (n ¼ 31) Cediranib Vessel size Permeability tumor-associated edema, reduced patient need for corticosteroids…”
BackgroundSelf-citationMicrovascular architecture in a mammary carcinoma: branching patterns and vessel dimensions.
Less, J. R., Skalak, T. C., Sevick, E., & Jain, R. K. (1991) · PubMed · Cited by 501
Self-citationAbramsson, A., Lindblom, P., & Betsholtz, C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318549 · Cited by 479
Algire, G. H., Chalkley, H. W., Legallais, F. Y., & Park, H. D. (1945) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/6.1.73 · Cited by 472 · cited 1×
“Solid tumors are the best characterized example, with seminal work first performed more than 70 years ago confirming the importance of an abundant blood supply for tumor growth (Ide et al. 1939; Algire and Chalkley 1945).”
BackgroundDeletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., Cheresh, D. A., & Johnson, R. S. (2008) · Nature · doi:10.1038/nature07445 · Cited by 471 · cited 5×
“…2006b; Segers et al. 2006; Cerniglia et al. 2009; Qayum et al. 2009; Cham et al. 2010. kAder et al. 2003; Hamzah et al. 2008; Kashiwagi et al. 2008; Stockmann et al. 2008; Maione et al. 2009; Mazzone et al. 2009; Skuli et al. 2009; Tsukada et al. 2009; Rolny et al. 2011. lYuan et al. 1996; Lee et…”
BackgroundInfluentialTargeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468 · cited 1×
“The angiopoietin-Tie2 pathway is perhaps the second most important EC-specific pathway regulating both healthy and tumor-associated angiogenesis (Suri et al. 1996; Huang et al. 2010).”
BackgroundDickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441 · cited 10×
“This has generally been accompanied by an increase in vascular maturity (the proportion of PVC-covered vessels), such that the treated vasculature resembles that of normal tissue more closely (Yuan et al. 1996; Inai et al. 2004; Tong et al. 2004; Dickson et al. 2007b).”
BackgroundInfluentialIshida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J. W., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022027 · Cited by 421 · cited 1×
“In the case of pegaptanib, preclinical work shows features of vascular normalization in response to treatment including a reduction in microvascular leakage, leukocyte adhesion, and choroidal neovascularization (Eyetech Study Group 2002; Ishida et al. 2003).”
BackgroundWillett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420 · cited 1×
“2) (Willett et al. 2004, 2005, 2009).”
Self-citationHerbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 415 · cited 1×
“Although almost all initial clinical trials combining chemotherapy with TKIs yielded disappointing results, recent success from this approach has been reported in a randomized phase 3 trial using an anti-VEGFR TKI with low inhibitory potency (Herbst et al. 2010).”
ResultTHE EYETECH STUDY GROUP (2002) · Retina · doi:10.1097/00006982-200204000-00002 · Cited by 415
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414 · cited 1×
“ECs exposed to low dose chemotherapy in vitro up-regulate expression of the antiangiogenic thrombospondin-1 (Bocci et al. 2003).”
BackgroundSorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394 · cited 2×
“…as Cold Spring Harb Perspect Med 2012;2:a006486 11 w w w .p er sp ec ti ve si n m ed ic in e. o rg mathematical index of vascular normalization (comprising various indirect markers of normalization) and found this to be a strong predictor of individual patient outcomes (Sorensen et al. 2009).”
BackgroundSelf-citationAngiogenesis drives psoriasis pathogenesis
Heidenreich, R., Röcken, M., & Ghoreschi, K. (2009) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2009.00669.x · Cited by 383 · cited 2×
“Underlying psoriatic angiogenesis, several proangiogenic factors including tumor necrosis factor-a (TNF-a), VEGF, HIFs, Interleukin (IL)-8, and angiopoietins, are all enriched in psoriatic skin (Heidenreich et al. 2009).”
BackgroundJain, R. K., Safabakhsh, N., Sckell, A., Chen, Y., Jiang, P., Benjamin, L., Yuan, F., & Keshet, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10820 · Cited by 374 · cited 2×
“We have shown that castration of mice bearing the androgen-dependent Shionogi carcinoma indirectly reduces tumoral VEGF expression, in turn inducing EC apoptosis, normalizing vessels structurally and functionally, and improving tumor oxygenation (Jain et al. 1998; HansenAlgenstaedt et al. 2000).”
BackgroundSelf-citationLeunig, M., Yuan, F., Menger, M. D., Boucher, Y., Goetz, A. E., Meßmer, K., & Jain, R. K. (1992) · PubMed · Cited by 370
Self-citationLebrin, F., Srun, S., Raymond, K., Martin, S., van den Brink, S., Freitas, C., Bréant, C., Mathivet, T., Larrivée, B., Thomas, J.-L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2131 · Cited by 369 · cited 1×
“Using a murine genetic model of HHT, Lebrin and colleagues found that the antiangiogenic agent thalidomide increased vessel maturity in telangiectatic regions (as evidenced by increased PVC coverage), hence normalizing vessels and attenuating vessel wall defects (Lebrin et al. 2010).”
Pericytes limit tumor cell metastasis
Xian, X. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25705 · Cited by 345
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343 · cited 1×
“Ang-2 inhibition operates not only through preventing Ang-2/Tie-2 interaction on ECs, but might also interfere with the proangiogenic activities of Tie-2 expressing monocytes (TEMs) (Coffelt et al. 2010; Mazzieri et al. 2011).”
BackgroundEffect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Wildiers, H., Guetens, G., De Boeck, G., Verbeken, E., Landuyt, B., Landuyt, W., de Bruijn, E. A., & van Oosterom, A. T. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601005 · Cited by 334 · cited 14×
“…Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009; Cerniglia et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b; Wildiers et al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and…”
BackgroundInfluentialYu, J., deMuinck, E. D., Zhuang, Z., Drinane, M., Kauser, K., Rubanyi, G. M., Qian, H. S., Murata, T., Escalante, B., & Sessa, W. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501444102 · Cited by 322 · cited 2×
“2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et al. 2005), TGF-b (Liu et al.”
BackgroundKamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309 · cited 9×
“…“normalization window”—a time period beginning with the appearance of a normalized vascular phenotype (typically within 1–2 days of starting treatment), and ending when features of normalization are lost (Tong et al. 2004; Winkler et al. 2004; Jain 2005b; Batchelor et al. 2007; Kamoun et al. 2009).”
BackgroundInfluentialSelf-citationGriffioen, A., Damen, C., Blijham, G., & Groenewegen, G. (1996) · Blood · doi:10.1182/blood.v88.2.667.bloodjournal882667 · Cited by 304
(2000) · PubMed · Cited by 295
Self-citationKozin, S. V., Boucher, Y., Hicklin, D. J., Böhlen, P., Jain, R. K., & Suit, H. D. (2001) · PubMed · Cited by 291
Self-citationDings, R. P. M., Loren, M., Heun, H., McNiel, E., Griffioen, A. W., Mayo, K. H., & Griffin, R. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2441 · Cited by 286 · cited 5×
“…et al. 2000; Lee et al. 2000; Kozin et al. 2001; Ader et al. 2003; Winkler et al. 2004; Ansiaux et al. 2005, 2006; Pore et al. 2006a; Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009; Cerniglia et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b;…”
BackgroundInfluentialDirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270 · cited 1×
“…after antiangiogenic therapy in certain animal models (Ebos et al. 2009; Paez-Ribes et al. 2009). dMazzone et al. 2009. eGriffioen et al. 1996; Dirkx et al. 2006. fGorski et al. 1999; Hansen-Algenstaedt et al. 2000; Lee et al. 2000; Kozin et al. 2001; Ader et al. 2003; Winkler et al. 2004;…”
BackgroundPore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3090 · Cited by 268 · cited 3×
“…al. 2010. jTeicher et al. 1995b; Jain et al. 1998; Bernsen et al. 1999; Cohen-Jonathan et al. 2001; Delmas et al. 2003; Ansiaux et al. 2005, 2006; Pore et al. 2006b; Segers et al. 2006; Cerniglia et al. 2009; Qayum et al. 2009; Cham et al. 2010. kAder et al. 2003; Hamzah et al. 2008; Kashiwagi…”
BackgroundVan de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256 · cited 3×
“…demonstrating a profound effect on tumor growth accompanied by angiogenesis inhibition, vessel maturation, resolution of hypoxia, and improved efficacy of chemotherapy (Fischer et al. 2007; Van de Veire et al. 2010), and others demonstrating limited effects on tumor growth (Bais et al. 2010).”
BackgroundNeuropilins in neoplasms: Expression, regulation, and function
Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.024 · Cited by 255 · cited 2×
“…integrins (Friedlander et al. 1995; Kurozumi et al. 2007; Skuli et al. 2009; Desgrosellier and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et al. 2005), TGF-b (Liu et…”
Background(1992) · PubMed · Cited by 252
Self-citationSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02760 · Cited by 239
Ide, A. (1939) · American Journal of Roentgenology · Cited by 234
Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., & Jooss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 232 · cited 1×
“…al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and Gallo 2009; J Liu, S Liao, B Diop-Frimpong, et al., unpubl. data. hHuang et al. 2002; Li et al. 2006; Manning et al. 2007; Hamzah et al. 2008; Shrimali et al. 2010.”
BackgroundAntiangiogenic therapy for cancer: current and emerging concepts.
Coiffier, B., & Reyes, F. (2005) · PubMed · Cited by 231
Falcón, B. L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J. V., Coxon, A., Oliner, J. D., & McDonald, D. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090391 · Cited by 224 · cited 3×
“…delivery of drugs or systemically administered molecules 8o 5p 3q 16 aYuan et al. 1996; Tong et al. 2004; Dickson et al. 2007b; Taguchi et al. 2008; Falcon et al. 2009; Juan et al. 2009; Kamoun et al. 2009; Chae et al. 2010; Koh et al. 2010; Primo et al. 2010. bJain et al. 1998; Izumi et al. 2002;…”
BackgroundInfluential(1991) · PubMed · Cited by 220
Self-citationMaione, F., Molla, F., Meda, C., Latini, R., Zentilin, L., Giacca, M., Seano, G., Serini, G., Bussolino, F., & Giraudo, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36308 · Cited by 219
Ranibizumab in neovascular age-related macular degeneration
Eng, K. T., & Kertes, P. J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.451 · Cited by 216 · cited 1×
“In turn, this normalized vessel phenotype dramatically alters the retinal microenvironment and has led to impressive clinical results (Gragoudas et al. 2004; Rosenfeld et al. 2006; Ferrara 2010), including improved visual acuity lasting for up to 24 mo after commencement of therapy.”
BackgroundSimultaneous measurement of RBC velocity, flux, hematocrit and shear rate in vascular networks
Kamoun, W. S., Chae, S.-S., Lacorre, D. A., Tyrrell, J. A., Mitre, M., Gillissen, M. A., Fukumura, D., Jain, R. K., & Munn, L. L. (2010) · Nature Methods · doi:10.1038/nmeth.1475 · Cited by 214 · cited 1×
“The haphazard and bizarre distribution of vessels leads to heterogeneous blood flow, sluggish in some regions and excessive in others (Jain 1988, 2005b; Kamoun et al. 2010).”
BackgroundSelf-citationManning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205 · cited 1×
“…al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and Gallo 2009; J Liu, S Liao, B Diop-Frimpong, et al., unpubl. data. hHuang et al. 2002; Li et al. 2006; Manning et al. 2007; Hamzah et al. 2008; Shrimali et al. 2010.”
BackgroundBressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203 · cited 1×
“In turn, this normalized vessel phenotype dramatically alters the retinal microenvironment and has led to impressive clinical results (Gragoudas et al. 2004; Rosenfeld et al. 2006; Ferrara 2010), including improved visual acuity lasting for up to 24 mo after commencement of therapy.”
Backgrounddi Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G., Auluck, P. K., Fazlollahi, L., Andronesi, O. C., Frosch, M. P., Wen, P. Y., Plotkin, S. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2602 · Cited by 199 · cited 1×
“In addition to these findings, studies reporting results of serial GBM biopsy and autopsy specimens before and after anti-VEGF therapy have suggested a pattern of structurally more normal vessels after therapy (Fischer et al. 2008; di Tomaso et al. 2011).”
ResultSelf-citationULTRASTRUCTURE OF THE CAPILLARY LOOPS IN THE DERMAL PAPILLAE OF PSORIASIS
Braverman, I. M., & Yen, A. (1977) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12485169 · Cited by 191 · cited 1×
“Psoriatic plaques show characteristic features of venous capillaries, as opposed to normal skin in which capillary loops show an arterial phenotype (Braverman and Yen 1977).”
BackgroundKashiwagi, S., Izumi, Y., Gohongi, T., Demou, Z. N., Xu, L., Huang, P. L., Buerk, D. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24015 · Cited by 188 · cited 1×
“…and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et al. 2005), TGF-b (Liu et al., submitted for publication), and interferon-b (Dickson et al. 2007a,c; Taylor et al.…”
BackgroundSelf-citationPerivascular nitric oxide gradients normalize tumor vasculature
Kashiwagi, S., Tsukada, K., Xu, L., Miyazaki, J., Kozin, S. V., Tyrrell, J. A., Sessa, W. C., Gerweck, L. E., Jain, R. K., & Fukumura, D. (2008) · Nature Medicine · doi:10.1038/nm1730 · Cited by 183 · cited 5×
“…and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et al. 2005), TGF-b (Liu et al., submitted for publication), and interferon-b (Dickson et al. 2007a,c; Taylor et al.…”
BackgroundInfluentialSelf-citationScaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182 · cited 1×
“Structurally, vessels are often dilated, weave a tortuous path, and show heterogeneity of distribution such that certain areas within a tumor are hypovascular and others hypervascular (Less et al. 1991, 1997; Yuan et al. 1996; Tong et al. 2004; Jain 2005b; Baish et al. 2011).”
BackgroundSelf-citationNasarre, P., Thomas, M., Kruse, K., Helfrich, I., Wolter, V., Deppermann, C., Schadendorf, D., Thurston, G., Fiedler, U., & Augustin, H. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3030 · Cited by 181 · cited 4×
“Similarly, wild-type tumors grown in Ang2 mice show an increase in PVC coverage, a reduction in vessel diameter, and a delayed early phase of tumor growth (Nasarre et al. 2009).”
BackgroundInfluentialRoh, H., Boucher, Y., Kalnicki, S., Buchsbaum, R., Bloomer, W. D., & Jain, R. K. (1991) · PubMed · Cited by 180
Self-citationJeziorska, M., & Woolley, D. E. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199906)188:2<189::aid-path336>3.0.co;2-n · Cited by 176
McCarty, M. F., Somcio, R. J., Stoeltzing, O., Wey, J., Fan, F., Liu, W., Bucana, C., & Ellis, L. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31334 · Cited by 175 · cited 1×
“…but limited clinical evidence to date Abbreviations: EMT, epithelial-to-mesenchymal transition. aKamoun et al. 2009. bXian et al. 2006; McCarty et al. 2007; Mazzone et al. 2009. cThis is controversial given recent reports of increased metastasis after antiangiogenic therapy in certain…”
BackgroundWhat brings pericytes to tumor vessels?
Jain, R. K., & Booth, M. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320087 · Cited by 175 · cited 1×
“A number of important molecules regulate pericyte–EC interaction, including platelet-derived growth factor-B (PDGF-B), Ang-1, transforming growth factor-b (TGF-b), and sphingosine-1-phosphate (S1P) in healthy tissues (Jain 2003; Jain and Booth 2003).”
BackgroundSelf-citationSchnell, C. R., Stauffer, F., Allegrini, P. R., O'Reilly, T., McSheehy, P. M. J., Dartois, C., Stumm, M., Cozens, R., Littlewood-Evans, A., García-Echeverría, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1044 · Cited by 174 · cited 2×
“…of normalization in response to inhibition of several oncogenes including HER-2 (Izumi et al. 2002), the PI3K-AKT-mTOR axis (Pore et al. 2006a; Schnell et al. 2008; Xue et al. 2008; Qayum et al. 2009), Ras (Cohen-Jonathan et al. 2001; Delmas et al. 2003; Qayum et al. 2009), and the epidermal…”
BackgroundEffect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy
Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., Hochberg, F. H., Weissleder, R., Carson, W., Chiocca, E. A., et al. (2007) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm229 · Cited by 172 · cited 3×
“These include the EC-specific integrins (Friedlander et al. 1995; Kurozumi et al. 2007; Skuli et al. 2009; Desgrosellier and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et…”
BackgroundKoh, Y. J., Kim, H.-Z., Hwang, S.-I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.001 · Cited by 166 · cited 2×
“…al. 1996; Tong et al. 2004; Dickson et al. 2007b; Taguchi et al. 2008; Falcon et al. 2009; Juan et al. 2009; Kamoun et al. 2009; Chae et al. 2010; Koh et al. 2010; Primo et al. 2010. bJain et al. 1998; Izumi et al. 2002; Delmas et al. 2003; Qayum et al. 2009. cHamzah et al. 2008; di Tomaso et…”
BackgroundThalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment
Ansiaux, R., Baudelet, C., Jordan, B. F., Beghein, N., Sonveaux, P., De Wever, J., Martinive, P., Grégoire, V., Feron, O., & Gallez, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.743.11.2 · Cited by 163
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
Bais, C., Wu, X., Yao, J. J., Yang, S., Crawford, Y., McCutcheon, K. M., Tan, C., Kolumam, G. A., Vernes, J.-M., Eastham‐Anderson, J., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.033 · Cited by 163 · cited 2×
“…demonstrating a profound effect on tumor growth accompanied by angiogenesis inhibition, vessel maturation, resolution of hypoxia, and improved efficacy of chemotherapy (Fischer et al. 2007; Van de Veire et al. 2010), and others demonstrating limited effects on tumor growth (Bais et al. 2010).”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02761 · Cited by 162
Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis
Schonthaler, H. B., Huggenberger, R., Wculek, S. K., Detmar, M., & Wagner, E. F. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907550106 · Cited by 160 · cited 1×
“After therapy, a reduction in vessel density and diameter was observed, corresponding to a reduction in severity of skin lesions (Schonthaler et al. 2009).”
BackgroundPore, N., Gupta, A. K., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. M., Koch, C. J., Hahn, S. M., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1239 · Cited by 157 · cited 4×
“…al. 2010. jTeicher et al. 1995b; Jain et al. 1998; Bernsen et al. 1999; Cohen-Jonathan et al. 2001; Delmas et al. 2003; Ansiaux et al. 2005, 2006; Pore et al. 2006b; Segers et al. 2006; Cerniglia et al. 2009; Qayum et al. 2009; Cham et al. 2010. kAder et al. 2003; Hamzah et al. 2008; Kashiwagi…”
BackgroundInfluentialTumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 146 · cited 26×
“2009), and the epidermal growth factor receptor (EGFR) (Cerniglia et al. 2009; Qayum et al. 2009; Johns et al. 2010).”
BackgroundInfluentialMcGee, M. C., Hamner, J. B., Williams, R. F., Rosati, S. F., Sims, T. L., Ng, C. Y., Gaber, M. W., Calabrese, C., Wu, J., Nathwani, A. C., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.12.010 · Cited by 137 · cited 2×
“…et al. 2005, 2006; Pore et al. 2006a; Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009; Cerniglia et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b; Wildiers et al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou…”
BackgroundAntiangiogenic Approaches to Age-Related Macular Degeneration Today
Bressler, N. M. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.048 · Cited by 136
Hagendoorn, J., Tong, R., Fukumura, D., Lin, Q., Lobo, J., Padera, T. P., Xu, L., Kucherlapati, R., & Jain, R. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2655 · Cited by 136 · cited 3×
“This leakiness, together with a relative absence of functional intratumoral lymphatic vessels (Padera et al. 2004; Hagendoorn et al. 2006), leads to a marked increase in the tumor interstitial fluid pressure (IFP) to a level that equilibrates with intravascular pressure, which results in reduced…”
BackgroundSelf-citationImpact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide
Zhou, Q., Guo, P., & Gallo, J. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4544 · Cited by 135 · cited 7×
“…Lee et al. 2000; Wildiers et al. 2003; Tong et al. 2004; Nakahara et al. 2006; Dickson et al. 2007b; Kurozumi et al. 2007; Taguchi et al. 2008; Zhou et al. 2008; Kamoun et al. 2009; Ohta et al. 2009; Zhou and Gallo 2009. mJain et al. 1998; Izumi et al. 2002; Ansiaux et al. 2005; Salnikov et…”
BackgroundInfluentialChae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3073 · Cited by 135 · cited 4×
“antagonist for Tie-2, enhancing tumor angiogenesis and destabilizing blood vessels (Chae et al. 2010).”
BackgroundInfluentialSelf-citationLocalization of endothelial proliferation and microvascular expansion in active plaque psoriasis
Creamer, D., Allen, M. H., Sousa, A. R., Poston, R. N., & Barker, J. N. (1997) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1997.01845.x · Cited by 133 · cited 1×
“Endothelial cells of psoriasis plaques also show enhanced proliferation (Creamer et al. 1997).”
Backgroundαvβ3/αvβ5 Integrins-FAK-RhoB: A Novel Pathway for Hypoxia Regulation in Glioblastoma
Skuli, N., Monferran, S., Delmas, C., Favre, G., Bonnet, J., Toulas, C., & Cohen-Jonathan Moyal, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2158 · Cited by 133 · cited 3×
“These include the EC-specific integrins (Friedlander et al. 1995; Kurozumi et al. 2007; Skuli et al. 2009; Desgrosellier and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et…”
BackgroundTeicher, B. A. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437479 · Cited by 132
Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., & di Tomaso, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3107 · Cited by 129 · cited 4×
“correlation between VEGF activity and growth rate in these tumors, anti-VEGF therapy inhibited tumor growth, an effect mediated primarily through an antiangiogenic effect (Wong et al. 2010).”
BackgroundInfluentialSelf-citationFlieger, D., Hainke, S., & Fischbach, W. (2006) · Annals of Hematology · doi:10.1007/s00277-006-0147-8 · Cited by 126 · cited 2×
“Small case series have suggested a beneficial role for antiangiogenic therapy in HHT. Bevacizumab, for example, has been shown to dramatically reduce the frequency of epistaxis and blood transfusion requirements (Flieger et al. 2006; Bose et al. 2009).”
BackgroundHansen‐Algenstaedt, N., Stoll, B. R., Padera, T. P., Dolmans, D. E. J. G. J., Hicklin, D. J., Fukumura, D., & Jain, R. K. (2000) · PubMed · Cited by 125
Self-citationCerniglia, G. J., Pore, N., Tsai, J. H., Schultz, S., Mick, R., Choe, R., Xing, X., Durduran, T., Yodh, A. G., Evans, S. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006539 · Cited by 125 · cited 6×
“2009), and the epidermal growth factor receptor (EGFR) (Cerniglia et al. 2009; Qayum et al. 2009; Johns et al. 2010).”
BackgroundInfluentialTaming Vessels to Treat Cancer
Jain, R. K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-56 · Cited by 122
Self-citationBevacizumab in Hereditary Hemorrhagic Telangiectasia
Bose, P., Holter, J. L., & Selby, G. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0901421 · Cited by 121 · cited 2×
“Small case series have suggested a beneficial role for antiangiogenic therapy in HHT. Bevacizumab, for example, has been shown to dramatically reduce the frequency of epistaxis and blood transfusion requirements (Flieger et al. 2006; Bose et al. 2009).”
BackgroundCay??-Thomasen, P., Werther, K., Nalla, A., g-Hansen, T. C. B., Nielsen, H. J., Stangerup, S., & Thomsen, J. (2005) · Otology & Neurotology · doi:10.1097/00129492-200501000-00017 · Cited by 117
Jain, R. K., Finn, A. V., Kolodgie, F. D., Gold, H. K., & Virmani, R. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0979 · Cited by 117 · cited 2×
“atherosclerotic plaque development is a young and relatively unexplored area, evidence does suggest that new vessel formation in the coronary plaque vasa vasorum is an important contributor to disease progression and plaque complications (Jeziorska and Woolley 1999; Kolodgie et al. 2003; Virmani et al. 2005; Jain et a…”
BackgroundSelf-citationdi Tomaso, E., London, N., Fuja, D., Logie, J., Tyrrell, J. A., Kamoun, W., Munn, L. L., & Jain, R. K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005123 · Cited by 116 · cited 3×
“…al. 2010; Koh et al. 2010; Primo et al. 2010. bJain et al. 1998; Izumi et al. 2002; Delmas et al. 2003; Qayum et al. 2009. cHamzah et al. 2008; di Tomaso et al. 2009; Nasarre et al. 2009; Van de Veire et al. 2010; Rolny et al. 2011. dInai et al. 2004; Tong et al. 2004; Nakahara et al. 2006;…”
BackgroundInfluentialSelf-citationGeometric Resistance and Microvascular Network Architecture of Human Colorectal Carcinoma
Less, J. R., Posner, M. C., Skalak, T. C., Wolmark, N., & Jain, R. K. (1997) · Microcirculation · doi:10.3109/10739689709148315 · Cited by 110 · cited 1×
“Structurally, vessels are often dilated, weave a tortuous path, and show heterogeneity of distribution such that certain areas within a tumor are hypovascular and others hypervascular (Less et al. 1991, 1997; Yuan et al. 1996; Tong et al. 2004; Jain 2005b; Baish et al. 2011).”
BackgroundSelf-citationThe role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy
DeClerck, K. (2010) · Frontiers in Bioscience · doi:10.2741/3616 · Cited by 109
Xue, Q., Hopkins, B., Perruzzi, C., Udayakumar, D., Sherris, D., & Benjamin, L. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2058 · Cited by 106 · cited 2×
“2002), the PI3K-AKT-mTOR axis (Pore et al. 2006a; Schnell et al. 2008; Xue et al. 2008; Qayum et al. 2009), Ras (Cohen-Jonathan et al.”
BackgroundNakahara, T., Norberg, S. M., Shalinsky, D. R., Hu-Lowe, D. D., & McDonald, D. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0923 · Cited by 102 · cited 3×
“…cHamzah et al. 2008; di Tomaso et al. 2009; Nasarre et al. 2009; Van de Veire et al. 2010; Rolny et al. 2011. dInai et al. 2004; Tong et al. 2004; Nakahara et al. 2006; Dickson et al. 2007b; Dings et al. 2007; Fischer et al. 2007; Zhou et al. 2008; Falcon et al. 2009; Juan et al. 2009; Kamoun et…”
BackgroundInfluentialHuang, Y., Snuderl, M., & Jain, R. K. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.005 · Cited by 100 · cited 1×
“The histidine-rich glycoprotein (HRG), through its down-regulation of PlGF, may mediate this process, inducing vessel normalization and also modifications in tumor-associated macrophages from a protumor (M2) to antitumor (M1) phenotype (Huang et al. 2011; Rolny et al. 2011).”
BackgroundSelf-citationSegmental Heterogeneity of Vasa Vasorum Neovascularization in Human Coronary Atherosclerosis
Gössl, M., Versari, D., Hildebrandt, H. A., Bajanowski, T., Sangiorgi, G., Erbel, R., Ritman, E. L., Lerman, L. O., & Lerman, A. (2010) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2009.10.009 · Cited by 95 · cited 1×
“As a result, intra-plaque hemorrhage can occur (particularly in noncalcified plaques, which have the highest vessel density and are more prone to rupture), accelerating plaque progression and rupture, and leading to myocardial infarction (Gossl et al. 2010).”
BackgroundDuda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94 · cited 1×
“More crucially, the pretreatment level of sVEGFR1, a marker of vascular normalization, correlated with treatment outcome and toxicity (Duda et al. 2010).”
BackgroundSelf-citationBhattacharya, A., Seshadri, M., Oven, S. D., Tóth, K., Vaughan, M. M., & Rustum, Y. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0212 · Cited by 93 · cited 4×
“…et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b; Wildiers et al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and Gallo 2009; J Liu, S Liao, B Diop-Frimpong, et al., unpubl. data. hHuang…”
BackgroundInfluentialDifferential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Zhou, Q., & Gallo, J. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-088 · Cited by 91
Teicher, B. A., Holden, S. A., Dupuis, N. P., Kakeji, Y., Ikebe, M., Emi, Y., & Goff, D. A. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666043 · Cited by 89
Cham, K. K. Y., Baker, J. H. E., Takhar, K. S., Flexman, J. A., Wong, M. Q., Owen, D. A., Yung, A., Kozlowski, P., Reinsberg, S. A., Chu, E. M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605727 · Cited by 87 · cited 2×
“…et al. 2001; Delmas et al. 2003; Ansiaux et al. 2005, 2006; Pore et al. 2006b; Segers et al. 2006; Cerniglia et al. 2009; Qayum et al. 2009; Cham et al. 2010. kAder et al. 2003; Hamzah et al. 2008; Kashiwagi et al. 2008; Stockmann et al. 2008; Maione et al. 2009; Mazzone et al. 2009; Skuli…”
BackgroundRajappa, M., Saxena, P., & Kaur, J. (2010) · Advances in clinical chemistry · doi:10.1016/s0065-2423(10)50006-4 · Cited by 85 · cited 2×
“Several proangiogenic factors serve as players in the retinal microenvironment (including FGF, PDGF, and PlGF), but VEGF overexpression by RPE cells (caused by focal hypoxia and abnormal thickening of Bruch’s membrane) is the most important (Bressler 2009b; Rajappa et al. 2010).”
BackgroundCayé‐Thomasen, P., Baandrup, L., Jacobsen, G. K., Thomsen, J., & Stangerup, S. (2003) · The Laryngoscope · doi:10.1097/00005537-200312000-00014 · Cited by 83
Segers, J., Fazio, V. D., Ansiaux, R., Martinive, P., Féron, O., Wallemacq, P. E., & Gallez, B. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.017 · Cited by 82 · cited 3×
“…et al. 1995b; Jain et al. 1998; Bernsen et al. 1999; Cohen-Jonathan et al. 2001; Delmas et al. 2003; Ansiaux et al. 2005, 2006; Pore et al. 2006b; Segers et al. 2006; Cerniglia et al. 2009; Qayum et al. 2009; Cham et al. 2010. kAder et al. 2003; Hamzah et al. 2008; Kashiwagi et al. 2008;…”
BackgroundHigh-grade glioma before and after treatment with radiation and Avastin: Initial observations
Fischer, I., Cunliffe, C. H., Bollo, R. J., Raza, S., Monoky, D., Chiriboga, L., Parker, E. C., Golfinos, J. G., Kelly, P. J., Knopp, E. A., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-042 · Cited by 79 · cited 2×
“…edema, reduced patient need for corticosteroids (Batchelor et al. 2007, 2010) High grade glioma (n ¼ 5) Bevacizumab Vascular arcades and glomeruloid vessels Fischer et al. 2008 Prostate carcinoma (n ¼ 10) Androgen ablation Pruning of immature vessels, PVC coverage Benjamin et al. 1999”
BackgroundResultPrimo, L., Seano, G., Roca, C., Maione, F., Gagliardi, P. A., Sessa, R., Martinelli, M., Giraudo, E., di Blasio, L., & Bussolino, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0507 · Cited by 75 · cited 4×
“These include the EC-specific integrins (Friedlander et al. 1995; Kurozumi et al. 2007; Skuli et al. 2009; Desgrosellier and Cheresh 2010; Primo et al. 2010), semaphorins (Bielenberg et al. 2006; Maione et al. 2009), members of the nitric oxide synthase family (Kashiwagi et al. 2005, 2008; Yu et…”
BackgroundInfluentialThe neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu‐Emerson, C., & Plotkin, S. R. (2009) · PubMed · Cited by 74
Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2429 · Cited by 73 · cited 2×
“We have recently found that diaphragmatic lymphatics in ovarian cancer–bearing mice have structural abnormalities not dissimilar from those found in tumor blood vessels, namely increased vessel density, diameter, and tortuosity (Liao et al. 2011).”
BackgroundSelf-citationHuang, X., Wong, M. K. K., Yi, H., Watkins, S. C., Laird, A., Wolf, S. F., & Gorelik, E. (2002) · PubMed · Cited by 72
The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
Moyal, E. C., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., & Bernhard, E. J. (2001) · PubMed · Cited by 71
Delmas, C., End, D. W., Rochaix, P., Favre, G., Toulas, C., & Moyal, E. C. (2003) · PubMed · Cited by 70
Liu, F., Wang, P., Jiang, X. L., Tan, G., Qiao, H., Jiang, H., Krissansen, G. W., & Sun, X. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00905.x · Cited by 67 · cited 1×
“First, and not surprisingly, down-regulating tumor HIF-1a expression inhibits tumor angiogenesis and might improve the efficacy of chemotherapy (Liu et al. 2008).”
BackgroundAntiangiogenesis Targeting Tumor Microenvironment Synergizes Glucuronide Prodrug Antitumor Activity
Ting-Yi, J., Roffler, S. R., Hou, H.-S., Huang, S., Chen, K., Leu, Y.-L., Prijovich, Z. M., Yu, C., Wu, C., Sun, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0090 · Cited by 61
Teicher, B. A., Dupuis, N. P., Robinson, M., Emi, Y., & Goff, D. A. (1995) · PubMed · Cited by 61
Ansiaux, R., Baudelet, C., Jordan, B. F., Crokart, N., Martinive, P., DeWever, J., Grégoire, V., Feron, O., & Gallez, B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1854 · Cited by 60 · cited 2×
“…Dirkx et al. 2006. fGorski et al. 1999; Hansen-Algenstaedt et al. 2000; Lee et al. 2000; Kozin et al. 2001; Ader et al. 2003; Winkler et al. 2004; Ansiaux et al. 2005, 2006; Pore et al. 2006a; Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009; Cerniglia et al. 2009; Tsukada et al.…”
BackgroundSalnikov, A. V., Roswall, P., Sundberg, C., Gardner, H., Heldin, N., & Rubin, K. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700252 · Cited by 58 · cited 1×
“…et al. 2008; Zhou et al. 2008; Kamoun et al. 2009; Ohta et al. 2009; Zhou and Gallo 2009. mJain et al. 1998; Izumi et al. 2002; Ansiaux et al. 2005; Salnikov et al. 2005; Bhattacharya et al. 2008, 2009; Schnell et al. 2008; Cerniglia et al. 2009. nDickson et al. 2007c; Kashiwagi et al. 2008; di…”
BackgroundAder, I., Delmas, C., Bonnet, J., Rochaix, P., Favre, G., Toulas, C., & Moyal, E. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207095 · Cited by 57 · cited 1×
“…et al. 2009. eGriffioen et al. 1996; Dirkx et al. 2006. fGorski et al. 1999; Hansen-Algenstaedt et al. 2000; Lee et al. 2000; Kozin et al. 2001; Ader et al. 2003; Winkler et al. 2004; Ansiaux et al. 2005, 2006; Pore et al. 2006a; Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009;…”
Bullitt, E., Lin, N. U., Smith, J. K., Zeng, D., Winer, E. P., Carey, L. A., Lin, W., & Ewend, M. G. (2007) · Radiology · doi:10.1148/radiol.2453061889 · Cited by 45 · cited 1×
“HER2þ breast cancer brain metastases (n ¼ 22) Lapatinib (indirect antiangiogenic) Vessel tortuosity Bullitt et al. 2007 12 Cite this article as Cold Spring Harb Perspect Med 2012;2:a006486 w w w .p er sp ec ti ve si n m ed ic in e. o rg Vestibular schwannomas are known to express VEGF and VEGFRs,…”
BackgroundZibert, J. R., Wallbrecht, K., Schön, M., Mir, L. M., Jacobsen, G. K., Trochon-Joseph, V., Bouquet, C., Villadsen, L. S., Cadossi, R., Skov, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41295 · Cited by 45 · cited 2×
“More recently, nonviral somatic delivery of the recombinant disintegrin domain (RDD) of metargidin, which interferes with the VEGF pathway and angiogenesis, was shown to lower cutaneous blood flow in psoriasis-affected mice and reduce disease severity (Zibert et al. 2010).”
BackgroundIdentification of Interferon-β-Stimulated Genes that Inhibit Angiogenesis In Vitro
Taylor, K. L., Leaman, D. W., Grane, R., Mechti, N., Borden, E. C., & Lindner, D. J. (2008) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2008.0030 · Cited by 43 · cited 2×
“, submitted for publication), and interferon-b (Dickson et al. 2007a,c; Taylor et al. 2008).”
BackgroundContinuous Delivery of IFN-β Promotes Sustained Maturation of Intratumoral Vasculature
Dickson, P. V., Hamner, J. B., Streck, C. J., Ng, C. Y., McCarville, M. B., Calabrese, C. R., Gilbertson, R. J., Stewart, C. F., Wilson, C., Gaber, M. W., et al. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0259 · Cited by 41 · cited 10×
“This has generally been accompanied by an increase in vascular maturity (the proportion of PVC-covered vessels), such that the treated vasculature resembles that of normal tissue more closely (Yuan et al. 1996; Inai et al. 2004; Tong et al. 2004; Dickson et al. 2007b).”
BackgroundInfluentialExpression of Angiogenic Growth Factors in Acoustic Neurinoma
Brieger, J., Bedavanija, A., Lehr, H., Maurer, J., & Mann, W. J. (2003) · Acta Oto-Laryngologica · doi:10.1080/00016480310005101 · Cited by 40 · cited 2×
“…Spring Harb Perspect Med 2012;2:a006486 w w w .p er sp ec ti ve si n m ed ic in e. o rg Vestibular schwannomas are known to express VEGF and VEGFRs, and the VEGF level within these tumors correlates with their growth rate (Brieger et al. 2003; CayeThomasen et al. 2003, 2005; Plotkin et al. 2009).”
BackgroundSuramin Treatment of Human Glioma Xenografts; Effects on Tumor Vasculature and Oxygenation Status
Bernsen, H. J. J. A., Rijken, P. F. J. W., Peters, J. P. W., Bakker, J. H., Boerman, R. H., Wesseling, P., & van der Kogel, A. J. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006363215260 · Cited by 39 · cited 1×
“…2007; Fischer et al. 2007; Eichhorn et al. 2008; Batra et al. 2009; Skuli et al. 2009; McGee et al. 2010. jTeicher et al. 1995b; Jain et al. 1998; Bernsen et al. 1999; Cohen-Jonathan et al. 2001; Delmas et al. 2003; Ansiaux et al. 2005, 2006; Pore et al. 2006b; Segers et al. 2006; Cerniglia et…”
BackgroundSorafenib-associated remission of psoriasis in hypernephroma: Case report
Fournier, C., & Tisman, G. (2010) · Dermatology Online Journal · doi:10.5070/d32z47h80w · Cited by 39
Bhattacharya, A., Tóth, K., Sen, A., Seshadri, M., Cao, S., Durrani, F. A., Faber, E. B., Repasky, E. A., & Rustum, Y. M. (2009) · Clinical Colorectal Cancer · doi:10.3816/ccc.2009.n.025 · Cited by 36 · cited 3×
“…et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b; Wildiers et al. 2003; Segers et al. 2006; Dickson et al. 2007a,b,c; Bhattacharya et al. 2008, 2009; Zhou et al. 2008; Juan et al. 2009; Zhou and Gallo 2009; J Liu, S Liao, B Diop-Frimpong, et al., unpubl. data. hHuang…”
BackgroundTaguchi, E., Nakamura, K., Miura, T., Shibuya, M., & Isoe, T. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00724.x · Cited by 36 · cited 2×
“…2011. lYuan et al. 1996; Lee et al. 2000; Wildiers et al. 2003; Tong et al. 2004; Nakahara et al. 2006; Dickson et al. 2007b; Kurozumi et al. 2007; Taguchi et al. 2008; Zhou et al. 2008; Kamoun et al. 2009; Ohta et al. 2009; Zhou and Gallo 2009. mJain et al. 1998; Izumi et al. 2002; Ansiaux et…”
BackgroundImprovement of Psoriasis During Sunitinib Therapy for Renal Cell Carcinoma
Narayanan, S., Agarwal, N., Callis-Duffin, K. P., & Batten, J. A. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181dd1aa5 · Cited by 35 · cited 4×
“6.1 and bevacizumab), antimurine VEGF antibodies, and the “VEGF-Trap” aflibercept; (2) inhibition of VEGFR2 function (using anti-VEGFR2 antibodies such as DC101 or receptor tyrosine kinase inhibitors [TKIs] which inhibit the kinase domain of VEGFRs).”
BackgroundInfluentialDas, P. K., de Boer, O. J., Visser, A., Verhagen, C. E., Bos, J. D., & Pals, S. T. (1994) · PubMed · Cited by 34
Eichhorn, M., Strieth, S., Luedemann, S., Kleespies, A., Nöth, U., Passon, A., Brix, G., Jauch, K. ‐., Bruns, C. J., & Dellian, M. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.7.5997 · Cited by 32 · cited 1×
“…and Gallo 2009. hMazzone et al. 2009. iHansen-Algenstaedt et al. 2000; Lee et al. 2000; Winkler et al. 2004; Dings et al. 2007; Fischer et al. 2007; Eichhorn et al. 2008; Batra et al. 2009; Skuli et al. 2009; McGee et al. 2010. jTeicher et al. 1995b; Jain et al. 1998; Bernsen et al. 1999;…”
BackgroundKeshtgarpour, M., & Dudek, A. Z. (2007) · Translational research · doi:10.1016/j.trsl.2007.01.003 · Cited by 30
Ohta, M., Kawabata, T., Yamamoto, M., Tanaka, T., Kikuchi, H., Hiramatsu, Y., Kamiya, K., Baba, M., & Konno, H. (2009) · Surgery Today · doi:10.1007/s00595-009-4020-y · Cited by 28 · cited 2×
“…2003; Tong et al. 2004; Nakahara et al. 2006; Dickson et al. 2007b; Kurozumi et al. 2007; Taguchi et al. 2008; Zhou et al. 2008; Kamoun et al. 2009; Ohta et al. 2009; Zhou and Gallo 2009. mJain et al. 1998; Izumi et al. 2002; Ansiaux et al. 2005; Salnikov et al. 2005; Bhattacharya et al. 2008,…”
BackgroundJohns, T. G., McKay, M. J., Cvrljevic, A. N., Gan, H. K., Taylor, C., Xu, H., Smyth, F. E., & Scott, A. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.027 · Cited by 23 · cited 18×
“2009), and the epidermal growth factor receptor (EGFR) (Cerniglia et al. 2009; Qayum et al. 2009; Johns et al. 2010).”
BackgroundInfluentialDickson, P. V., Hagedorn, N. L., Hamner, J. B., Fraga, C. H., Ng, C. Y., Stewart, C. F., & Davidoff, A. M. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.09.052 · Cited by 17 · cited 10×
“This has generally been accompanied by an increase in vascular maturity (the proportion of PVC-covered vessels), such that the treated vasculature resembles that of normal tissue more closely (Yuan et al. 1996; Inai et al. 2004; Tong et al. 2004; Dickson et al. 2007b).”
BackgroundInfluentialTaming Vessels to Treat Cancer
Jain, R. K. (2008) · Scientific American A Matter of Time · doi:10.1038/scientificamerican0708-64sp · Cited by 16
Self-citationBatra, S., Matsumoto, S., Hyodo, F., Mitchell, J., & Krishna, M. C. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.07.120 · Cited by 6 · cited 2×
“…Kozin et al. 2001; Ader et al. 2003; Winkler et al. 2004; Ansiaux et al. 2005, 2006; Pore et al. 2006a; Dings et al. 2007; Kashiwagi et al. 2008; Batra et al. 2009; Cerniglia et al. 2009; Tsukada et al. 2009; McGee et al. 2010. gTeicher et al. 1995a,b; Wildiers et al. 2003; Segers et al. 2006;…”
Background
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050
Metadata
- Authors
- Goel, S., Wong, A. H.-K., & Jain, R. K.
- Affiliations
- Harvard University (US)
- ORCID
- Goel, S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-18
- Volume
- 2
- Issue
- 3
- Pages
- a006486-a006486
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282493
- OpenAlex
- W2115852392
- Cited by
- 352
- References
- 191
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 22 · 2023: 27 · 2022: 18 · 2021: 31 · 2020: 30 · 2019: 23 · 2018: 30 · 2017: 38 · 2016: 29 · 2015: 28 · 2014: 21 · 2013: 13 · 2012: 5
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- US-UK Fulbright Commission
- Fulbright Australia
- National Institutes of Health (W81XWH, CA126642, CA115767, R01-CA85140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, R01 CA 85140, R01CA085140, P01CA080124, R01CA126642, P01-CA-80124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- vascular normalization, pathological angiogenesis, anti-angiogenic therapy, tumor vasculature, tumor microenvironment, solid tumors
- MeSH terms
- Cytotoxins, Humans, Macular Degeneration, Neoplasms, Neuroma, Acoustic, Psoriasis, Telangiectasia, Hereditary Hemorrhagic, Disease Progression, Neovascularization, Physiologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Angiopoietin-2, Microvessels, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.